Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index
Innovent Biologics, a biopharmaceutical company, announced its inclusion in the Hang Seng China Enterprises Index (HSCEI), effective December 6, 2021. This index comprises 50 leading Chinese enterprises listed in Hong Kong, highlighting Innovent's market cap and trading volume. It is the first biopharmaceutical company listed under Chapter 18A to be included. CFO Ronald Ede emphasized the significance of this recognition as a milestone in Innovent's growth, aiming to evolve into a global biopharma leader.
- Inclusion in the prestigious HSCEI may attract additional capital inflow from passive index funds.
- Innovent is the first biopharmaceutical company listed under Chapter 18A to be included in the HSCEI.
- None.
SAN FRANCISCO and SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces the Company's stock is included in the Hang Seng China Enterprises Index (HSCEI) according to the Hang Seng Indexes Company's latest results of review. The inclusion will take effect on December 6, 2021.
The HSCEI is one of the most influential indexes in the Hong Kong and global stock markets, as constituted by 50 leading China enterprises listed on the Hong Kong Stock Exchanges with outstanding market cap and trading volume. Innovent is the first and only biopharmaceutical company listed under Chapter 18A of the Hong Kong Stock Exchanges to be included in the HSCEI, and the inclusion could indicate potential additional capital inflow from passive index funds.
Mr. Ronald Ede, Executive Director and CFO of Innovent, stated, "We are excited that our stock is included into the HSCEI, following the successful inclusion in the Hang Seng Composite Index and the Stock Connect last year. The recognition by capital market is another key milestone in the tenth year's journey of Innovent. As for the next decade, Innovent will be fully committed to transforming ourselves from a leading Chinese biopharma to a world-class global biopharma company equipped with the strategy of innovation and globalization. We sincerely appreciate the long-term trust from our patients, medical community, employees and shareholders along the journey. We will continue being devoted to our mission of'To develop and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.'"
About Innovent
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 26 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products approved for marketing in China – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) , one NDA under NMPA review, a Biologics License Application (BLA) for sintilimab accepted for review in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 15 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com and www.linkedin.com/company/innovent-biologics/.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
View original content:https://www.prnewswire.com/news-releases/innovent-announces-inclusion-of-the-companys-stock-01801hk-in-the-hang-seng-china-enterprises-index-301429551.html
SOURCE Innovent Biologics
FAQ
What does Innovent's inclusion in the HSCEI mean for investors?
When does Innovent's inclusion in the HSCEI take effect?
What is the significance of the HSCEI for Innovent?
Is Innovent the only biopharmaceutical company in the HSCEI?
